Literature DB >> 19386691

Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia.

S Al-Saleh1, M Mei-Zahav, M E Faughnan, I B MacLusky, S Carpenter, M Letarte, F Ratjen.   

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterised by vascular dysplasia complicated by visceral arteriovenous malformations (AVMs). To date, the diagnostic yield of screening procedures for pulmonary and cerebral AVMs in children with definite or potential HHT is not well defined. The aim of the present study was to prospectively evaluate the diagnostic yield of a screening protocol for pulmonary and cerebral AVMs in children with either a definite or potential HHT diagnosis. All children referred for evaluation for HHT between 1996 and 2008 were included in the present analysis. Screening tests for AVMs included chest computed tomography and brain magnetic resonance imaging. 61 children with a definite clinical and/or genetic diagnosis of HHT were asymptomatic for visceral AVMs at their first baseline assessment (mean+/-SD age 8.7+/-4.7 yrs; range 0-17.0 yrs). Of these, 15 (25%) had pulmonary and/or cerebral AVMs diagnosed on initial screening tests. Pulmonary AVMs predominated in paediatric HHT patients (14 out of 15 patients) and were found in eight children aged <10 yrs. 55 children had a potential HHT diagnosis as they fulfilled only one or two HHT clinical diagnostic criteria and did not have a confirmatory genetic diagnosis (age 10.9+/-4.8 yrs; range 0-17.9 yrs). None of these children had pulmonary or cerebral AVMs on initial screening tests. The present data suggest that children with a definite HHT diagnosis have a high frequency of pulmonary AVMs even when clinically asymptomatic. In contrast, no AVMs were observed in children not fulfilling HHT diagnostic criteria. Genetic testing appears to be useful in defining an at-risk group for pulmonary AVMs in childhood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386691     DOI: 10.1183/09031936.00030009

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Neurovascular Manifestations of Hereditary Hemorrhagic Telangiectasia: A Consecutive Series of 376 Patients during 15 Years.

Authors:  W Brinjikji; V N Iyer; V Yamaki; G Lanzino; H J Cloft; K R Thielen; K L Swanson; C P Wood
Journal:  AJNR Am J Neuroradiol       Date:  2016-03-24       Impact factor: 3.825

Review 2.  Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era.

Authors:  Jamie McDonald; Whitney Wooderchak-Donahue; Chad VanSant Webb; Kevin Whitehead; David A Stevenson; Pinar Bayrak-Toydemir
Journal:  Front Genet       Date:  2015-01-26       Impact factor: 4.599

3.  Targeting under-diagnosis in hereditary hemorrhagic telangiectasia: a model approach for rare diseases?

Authors:  Giuseppe A Latino; Dale Brown; Richard H Glazier; Jonathan T Weyman; Marie E Faughnan
Journal:  Orphanet J Rare Dis       Date:  2014-07-25       Impact factor: 4.123

4.  Comorbidity among HHT patients and their controls in a 20 years follow-up period.

Authors:  Katrine Saldern Aagaard; Anette Drøhse Kjeldsen; Pernille Mathiesen Tørring; Anders Green
Journal:  Orphanet J Rare Dis       Date:  2018-12-14       Impact factor: 4.123

5.  Pulmonary arteriovenous malformations in children with hereditary hemorrhagic telangiectasia: a longitudinal study.

Authors:  Katie L Mowers; Lynn Sekarski; Andrew J White; R Mark Grady
Journal:  Pulm Circ       Date:  2018-06-19       Impact factor: 3.017

6.  Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.

Authors:  Fabio E Ospina; Alex Echeverri; Iván Posso-Osorio; Lina Jaimes; Jaiber Gutierrez; Gabriel J Tobón
Journal:  Colomb Med (Cali)       Date:  2017-06-30

7.  Genotype-Phenotype Correlations in Children with HHT.

Authors:  Alexandra Kilian; Giuseppe A Latino; Andrew J White; Dewi Clark; Murali M Chakinala; Felix Ratjen; Jamie McDonald; Kevin Whitehead; James R Gossage; Doris Lin; Katharine Henderson; Jeffrey Pollak; Justin P McWilliams; Helen Kim; Michael T Lawton; Marie E Faughnan
Journal:  J Clin Med       Date:  2020-08-22       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.